Omalizumab (Xolair)

A previous CADTH Common Drug Review (CDR) of the use of omalizumab for allergic asthma in 2006 led to the recommendation by the Canadian Expert Drug Advisory Committee that omalizumab not be reimbursed due to: insufficient evidence that omalizumab improves exacerbations that lead to hospitalizations...

Full description

Bibliographic Details
Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Published: Ottawa (ON) CADTH September 2017, 2017
Series:Common drug review clinical review report
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Table of Contents:
  • Includes bibliographical references